ACM
RNAC icon

ADAR1 Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

ADAR1 Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
+98,877
New +$732K 0.05% 166

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's RNAC Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 98,877 shares worth $1.03M. The stake represents 0.05% of the portfolio and ranks #166 among its holdings.

95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • ADAR1 Capital Management held 98,877 shares of Cartesian Therapeutics worth $1.03M as of Q2 2026.
  • Cartesian Therapeutics was a new ADAR1 Capital Management position in Q2 2026.
  • Cartesian Therapeutics made up 0.05% of ADAR1 Capital Management's portfolio in Q2 2026, its #166 holding.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.